Thu Sep 19 08:59:35 UTC 2024: ## Arizona State Retirement System Invests in Kiniksa Pharmaceuticals

**Phoenix, AZ – September 19, 2024** – The Arizona State Retirement System has acquired a new position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) during the second quarter, according to HoldingsChannel.com. The firm purchased 11,192 shares of the company’s stock, valued at approximately $209,000.

This investment follows a trend of other hedge funds increasing or decreasing their stakes in Kiniksa Pharmaceuticals. Notable among these are Hhlr Advisors LTD., who acquired a new position in the first quarter valued at around $61,868,000, and Granahan Investment Management LLC, who boosted their position by 35.2% in the fourth quarter.

Meanwhile, insider John F. Paolini sold 60,692 shares of Kiniksa Pharmaceuticals stock on September 3rd, for a total value of $1,585,275.04. CFO Mark Ragosa also sold 24,248 shares on July 23rd, for a total of $601,107.92. Insiders have sold a total of 260,564 shares of company stock valued at $6,727,929 over the past ninety days.

Kiniksa Pharmaceuticals, a biopharmaceutical company, focuses on developing therapeutic medicines for patients suffering from debilitating diseases. The company reported earnings per share of ($0.06) for the second quarter, exceeding analyst expectations. Revenue for the quarter reached $108.30 million, surpassing the consensus estimate of $90.60 million.

Analysts predict that Kiniksa Pharmaceuticals will post -0.31 earnings per share for the current fiscal year. Wedbush raised their target price on the company to $34.00 and gave it an “outperform” rating, while Jefferies Financial Group assumed coverage on the company with a “buy” rating and a $40.00 price objective. Overall, the stock currently has an average rating of “Buy” and an average target price of $33.60.

**To learn more about Kiniksa Pharmaceuticals, visit HoldingsChannel.com for the latest 13F filings and insider trades.**

Read More